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 ABSTRACT  Children and young adults with glioblastoma (GBM) have a median survival rate of 
only 12 to 15 months, and these GBMs are clinically and biologically distinct from 
histologically similar cancers in older adults. They are defi ned by highly specifi c mutations in the gene 
encoding the histone H3.3 variant  H3F3A , occurring either at or close to key residues marked by meth-
ylation for regulation of transcription—K27 and G34. Here, we show that the cerebral hemisphere-
specifi c G34 mutation drives a distinct expression signature through differential genomic binding of 
the K36 trimethylation mark (H3K36me3). The transcriptional program induced recapitulates that of 
the developing forebrain, and involves numerous markers of stem-cell maintenance, cell-fate decisions, 
and self-renewal. Critically,  H3F3A G34 mutations cause profound upregulation of  MYCN , a potent 
oncogene that is causative of GBMs when expressed in the correct developmental context. This driving 
aberration is selectively targetable in this patient population through inhibiting kinases responsible for 
stabilization of the protein. 
 SIGNIFICANCE: We provide the mechanistic explanation for how the fi rst histone gene mutation in 
human disease biology acts to deliver MYCN, a potent tumorigenic initiator, into a stem-cell compart-
ment of the developing forebrain, selectively giving rise to incurable cerebral hemispheric GBM. Using 
synthetic lethal approaches to these mutant tumor cells provides a rational way to develop novel and 
highly selective treatment strategies.  Cancer Discov; 3(4); xxx–xxx. ©2013 AACR. 
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 INTRODUCTION 
 The clinical and molecular differences observed in glioblas-
toma (GBM) of children and young adults compared with the 
more common, histologically similar lesions in older adults is 
strongly suggestive of a distinct underlying biology ( 1 ). The 
identifi cation of unique and highly specifi c mutations in the 
gene encoding the histone H3.3 variant  H3F3A in GBM of 
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children and young adults has recently provided defi nitive proof 
of this hypothesis ( 2 ). However, a mechanism was lacking for how 
mutations at or close to key residues associated with posttransla-
tional modifi cation of the histone tail led to tumorigenesis. 
 We have sought to address this by examining how the dif-
ferences in clinical presentation, anatomic location, and gene 
expression associated with the different  H3F3A mutations are 
manifested. By exploiting the only known G34-mutant model 
system, we show that differential binding of the H3K36 trime-
thyl mark underpins these processes and identify MYCN as the 
oncogenic driver during forebrain development, providing a 
novel avenue for targeted therapy in children with these tumors. 
 RESULTS 
 Initial evidence suggested a distinct gene expression signa-
ture associated with mutations at the K27 (lysine to methio-
nine, K27M) versus G34 (glycine to either arginine, G34R, or 
valine, G34V) residues ( 2 ). We validated these data by identify-
ing differential expression patterns for mutations with G34 
versus K27 mutations in 2 independent datasets for which 
mutation data were either publicly available or were ascertained 
in our laboratory (refs.  2, 3 ;  Fig. 1 ). In both instances, highly 
signifi cant differential gene expression was noted between 
G34-mutant tumors and K27 or wild-type cases ( Fig. 1A and 
C ), which was consistent across the datasets as assessed by gene 
set enrichment analysis (GSEA;  Figs. 1B and D ) with enrich-
ment scores (ES) of 0.833 to 0.943 and  P (family-wise error rate; 
FWER) and  q (false discovery rate; FDR) values of 0.0 to 0.04. 
Given the considerable overlap in gene expression signatures 
between studies, we subsequently utilized an integrated data-
set (Supplementary Table S1), where hierarchical clustering 
resolved G34- and K27-mutant tumors from a more hetero-
geneous wild-type subgroup ( Fig. 1E ), confi rmed by k-means 
consensus clustering ( Fig. 1F ). These subgroups also showed 
important clinical differences, as previously described ( 2 ), with 
K27-mutant tumors arising in younger children (peak age 7 
years;  P = 0.0312,  t test;  Fig. 1G ) and having a worse clinical out-
come ( P = 0.0164, log-rank test;  Fig. 1H ) compared with G34 
tumors (peak age 14 years) and  H3F3A wild-type. There were 
no signifi cant transcriptional or clinicopathologic differences 
between G34R and G34V tumors, although a lack of samples 
of the latter ( n = 2) precludes robust analyses. 
 To understand the functional signifi cance of  H3F3A muta-
tions in cerebral hemispheric tumors, we turned to a well-
characterized ( 4 ) model of pediatric GBM, the KNS42 cell 
line, which was derived from a 16-year-old patient and har-
bors the G34V mutation ( Fig. 2A ). In contrast to the reported 
data in a single pediatric GBM sample with G34R ( 2 ), KNS42 
cells did not show increased levels of total histone H3K36 tri-
methylation compared with a panel of  H3F3A wild-type pedi-
atric glioma cells ( Fig.  2B , Supplementary Fig.  S1). KNS42 
cells harbor a nonsynonymous coding change of  ATRX 
(Q891E) that appears in the single-nucleotide polymorphism 
databases (rs3088074), and Western blot analysis shows no 
diminution of protein levels. As ATRX is a known chaper-
one of histone H3.3 to the telomeres, a wild-type protein 
would not be expected to convey the alternative lengthening 
of telomeres (ALT) phenotype, as observed (Supplementary 
Fig. S2); however, this ought not play a signifi cant role in gene 
transcription as deposition of H3.3 in euchromatin is carried 
out by alternative chaperones such as HIRA. 
 We conducted chromatin immunoprecipitation linked to 
next-generation whole genome sequencing (ChIP-Seq) for 
H3K36me3 to test the hypothesis that, rather than total 
H3K36me3, the G34V mutation may instead result in differ-
ential binding of the trimethyl mark throughout the genome. 
Compared with  H3F3A wild-type SF188 pediatric GBM cells, 
H3K36me3 was found to be signifi cantly differentially bound 
in KNS42 cells at 5,130 distinct regions of the genome cor-
responding to 156 genes (DESeq  P < 0.05, overall fold change 
>2, contiguous median coverage >2; Supplementary Table S2). 
These observations were not due to differential gene amplifi -
cation, as concurrent whole genome DNA sequencing showed 
that these bound genes were not found in regions on cell 
line-specifi c copy number alterations ( Fig. 2C ; Supplementary 
Fig. S3 and Supplementary Table S2). As the H3K36 residue 
is regarded as an activating mark for gene expression ( 5 ), we 
concurrently conducted ChIP-Seq for RNA polymerase II to 
produce a read out of transcriptional activity, and observed 
a signifi cant correlation between H3K36me3 and RNA 
polymerase II binding for the 156 differentially bound genes 
( R 2 = 0.923,  P < 0.0001;  Fig. 2D ). By integrating the H3K36me3 
and RNA polymerase II data, we derived a ranked list of 
differentially trimethyl-bound and expressed genes ( Fig. 2E ). 
Interrogating this ranked list using our integrated pediatric 
GBM expression dataset showed highly signifi cant enrich-
ment for G34-associated gene signatures in the differentially 
bound and expressed genes in G34-mutant KNS42 cells (ES = 
0.84–0.86, FWER  P = 0.02–0.03; FDR  q = 0.03–0.04;  Fig. 2F ). 
 To investigate the functions of the transcriptional pro-
grams targeted by this novel mechanism, we conducted gene 
ontology analysis of the differentially bound and expressed 
genes. These data revealed highly signifi cant enrichment of 
the processes involved in forebrain and cortex development, 
as well as differentiation of neurons and regulation of cell 
proliferation ( Fig. 2G ). We identifi ed a subset of 16 genes to 
be part of the core enrichment group showing signifi cant 
overlap between G34-mutant pediatric GBM specimens and 
transcription driven by differential binding of H3K36me3 
in KNS42 cells (Supplementary Table S3). By mapping the 
expression of these genes to published signatures of restricted 
spatiotemporal areas of brain development ( 6 ), we noted 
highly elevated levels at embryonic and early fetal time-points, 
which rapidly tailed off through mid-late fetal development 
and postnatal and adult periods ( Fig. 2H ). Expression of the 
G34 core enrichment genes was particularly pronounced in 
the early fetal amygdala, inferior temporal cortex, and the cau-
dal, medial, and lateral ganglionic eminences ( Fig. 2H ). Devel-
opmental expression patterns of G34 mutation-associated 
genes were in contrast to those observed with K27 mutation 
signatures derived from pediatric GBM specimens, which 
correlated with those of the embryonic upper rhombic lip, 
early-mid fetal thalamic, and cerebellar structures, and peaked 
during the mid-late fetal period (Supplementary Fig. S4). 
 Specifi cally, the G34 mutation drives expression of numerous 
highly developmentally regulated transcription factors, includ-
ing as an exemplar  DLX6 (distal-less homeobox 6), a homeobox 
transcription factor which plays a role in neuronal differen-
tiation in the developing forebrain ( 7 ). The highly signifi cant 
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 Figure 1.   Distinct molecular and clinical correlates of  H3F3A mutation subgroups. A, heatmap representing differential gene expression signatures 
between G34 versus K27, and G34 versus wild-type, pediatric GBM specimens identifi ed by Paugh and colleagues (3). Top 100 differentially expressed 
genes are shown for each comparison. B, gene set enrichment analysis (GSEA) for differential gene expression signatures identifi ed by Schwartzentruber
and colleagues (2) versus those from Paugh and colleagues (3). Top, G34 versus K27: enrichment score (ES) = 0.833,  P [family-wise error rate (FWER)] = 0.0, 
 q [false discovery rate (FDR)] = 0.0. Bottom, G34 versus wild-type: ES = 0.94, FWER  P = 0.0, FDR  q = 0.0. C, heatmap representing differential gene 
expression signatures between G34 versus K27, and G34 versus wild-type, pediatric GBM specimens from (2). Top 100 differentially expressed genes 
are shown for each comparison. D, GSEA for differential gene expression signatures identifi ed in (3) versus those in (2). Top, G34 versus K27: ES = 0.88, 
FWER  P = 0.03, FDR  q = 0.04. Bottom, G34 versus wild-type: ES = 0.90, FWER  P = 0.0, FDR  q = 0.0. E, hierarchical clustering of the integrated gene 
expression datasets, highlighting specifi c clusters of G34- and K27-mutant tumors, distinct from a more heterogeneous group of wild-type cases. G34V 
tumors are represented by asterisks. F, K-means consensus clustering fi nds the most stable number of subgroups to be 3, marked by  H3F3A mutation 
status. G, K27- and G34-mutant pediatric GBM in our integrated dataset have distinct age incidence profi les, with K27 tumors peaking at 7 years in 
contrast to G34 at age 14. The 2 G34V tumors were diagnosed at age 14 and 20. H, Kaplan–Meier plot for overall survival of pediatric patients with GBM 
stratifi ed by  H3F3A status. K27-mutant tumors have signifi cantly shorter survival than G34 ( P = 0.0164, log-rank test). A single G34V case for which 
data were available had an overall survival of 1.4 years. wt, wild-type. 
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 Figure 2.   Differential binding of H3K36me3 in G34-mutant KNS42 cells drives pediatric GBM expression signatures. A, Sanger sequencing trace for KNS42 
pediatric GBM cells reveals a heterozygous c.104G>T p.(Gly34Val)  H3F3A mutation. B, Western blot analysis for mono-(me1), di-(me2), and tri-(me3) methylated 
histone H3 in G34-mutant KNS42 and wild-type (wt) pediatric glioma cell lines. Total H3 is used as an extracted histone loading control. C, Circos plot representing 
the KNS42 genome, aligned with chromosomes 1 to X running clockwise from 12 o’clock. Outer ring, H3K36me3 ChIP-Seq binding. Gray, all binding; blue, differen-
tial binding in KNS42 versus SF188. Selected differentially bound developmental transcription factors and pluripotency genes are labeled. Inner ring, DNA copy 
number. Green points, copy number gain; black points, normal copy number; red points, copy number loss. Single base mutations in selected genes ( H3F3A :G34V 
and  TP53 :R342*) are labeled inside the circle. D, correlation plot of RNA polymerase II versus H3K36me3 for 65 differentially trimethyl-bound regions by ChIP-
Seq in KNS42 cells.  R 2 = 0.66;  P < 0.0001. E, heatmap representing a ranked list of differentially bound H3K36me3 and RNA polymerase II in G34V KNS42 versus 
wild-type SF188 cells, with top 20 genes listed. F, GSEA for preranked differentially bound genes identifi ed in ChIP-Seq versus those in the integrated gene 
expression datasets. Top, G34 versus K27: ES = 0.86, FWER  P = 0.03, FDR  q = 0.03. Bottom, G34 versus wild-type: ES = 0.84, FWER  P = 0.02, FDR  q = 0.04. 
G, DAVID gene ontology analysis for preranked list of differentially bound genes identifi ed in ChIP-Seq. Fold enrichment of processes are plotted and colored by 
FDR  q value. H, top, mean expression of the G34 core enrichment signature in a temporal gene expression dataset of human brain development. Period 1, embryo-
nal; periods 2–7, fetal; periods 8–12, postnatal; periods 13–15, adulthood. Bottom, heatmap representing spatial differences in G34 core enrichment signature 
expression in structures within embryonic and early fetal development, with highest levels mapping to the ganglionic eminences and amygdala. 
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 differential H3K36me3 and RNA polymerase II binding observed 
by ChIP-Seq ( Fig.  3A ) was validated by ChIP-qPCR ( Fig.  3B ), 
and expression of  DLX6 was noted to be signifi cantly higher 
in G34 pediatric GBM samples than K27-mutant or wild-type 
tumors in the integrated gene expression datasets at the mRNA 
level ( Fig. 3C ), and at the protein level in a tissue microarray com-
prising 46 pediatric and young adult GBM cases ( Fig. 3D and 
Supplementary Table S4). Other similarly validated forebrain 
development-associated transcription factors included  ARX ( 8 ), 
 DLX5 ( 7 ),  FOXA1 ( 9 ),  NR2E1 ( 10 ),  POU3F2 ( 11 ), and  SP8 (ref.  12 ; 
Supplementary Fig. S5–S10). Moreover, a number of key deter-
minants of cell fate were also found to be differentially bound by 
H3K36me3 and expressed in G34-mutant cells. These included 
 MSI1 (Musashi-1; ref.  13 ; Supplementary Fig. S11);  EYA4 ( eyes 
absent homolog 4; ref.  14 ; Supplementary Fig. S12); and  SOX2 , 
which is required for stem cell maintenance ( Fig. 3E–H ). 
 Strikingly, the most signifi cant differentially bound and 
expressed gene in our G34-mutant KNS42 cells was  MYCN 
(33-fold H3K36me3 compared with SF188, DESeq  P = 7.94 × 
10 −8 ; 60-fold RNA Pol II, DESeq  P = 1.59 × 10 −9 ;  Fig. 4A–D ). 
Of note, a small number of  H3F3A wild-type tumors also 
expressed high levels of  MYCN , and were found to be  MYCN 
gene amplifi ed ( Fig. 4C ). However, amplifi cation was not seen 
in G34-mutant tumors, which parallels observations in dif-
fuse intrinsic pontine glioma where  MYCN amplifi cation was 
found in wild-type, but not K27-mutant, tumors ( 15 ). Trans-
duction of the G34V mutation into normal human astro-
cytes (NHA) and transformed human fetal glial cells (SVG) 
conferred an approximately 2- to 3-fold increase in  MYCN 
transcript levels over wild-type–transduced controls, validat-
ing these observations (Supplementary Fig. S13).  H3F3A G34 
mutation may therefore represent an alternative mechanism 
of enhancing expression levels of MYCN in pediatric GBM. 
 Targeting MYCN is an attractive therapeutic intervention 
in tumors harboring gene mutation such as neuroblastoma 
( 16 ), and direct inhibition by siRNA knockdown in KNS42 
cells reduced cell viability in proportion to the reduction of 
protein levels observed ( Fig. 4E ). Pharmacologic agents that 
directly inhibit Myc transcription factors, however, remain 
elusive. We therefore carried out a synthetic lethal screen to 
ascertain how we might target these  H3F3A G34-mutant, 
MYCN-driven tumors in the clinic. We utilized a series of 
siRNAs directed against 714 human kinases against our panel 
of pediatric glioma cell lines to identify those which conferred 
selective cell death to the MYCN-expressing KNS42 cells 
versus wild-type, non-MYCN–expressing controls ( Fig.  4F ). 
The most signifi cant synthetically lethal hits in the G34-
mutant cells compared with  H3F3A wild-type were kinases 
 Figure 3.   G34 induces a transcriptional program linked to forebrain development and self-renewal.  DLX6 : A, ChIP-Seq of H3K36me3 and RNA 
polymerase II binding for G34-mutant KNS42 (blue) and wild-type (wt) SF188 cells (gray) for the  DLX6 locus, which also encompasses the transcripts 
 DLX5 ,  DLX6-AS1 , and  DLX6-AS2 . B, validation of ChIP-Seq data by ChIP-qPCR using specifi c primers targeting  DLX6 . Blue bars, KNS42; gray, SF188. ***, 
 P < 0.0001,  t test. C, boxplot of  DLX6 expression in the integrated pediatric GBM samples stratifi ed by  H3F3A status. Blue box, G34; green, K27; gray, 
wild-type. ***,  P < 0.001, ANOVA. D, top, immunohistochemistry for DLX6 protein in a G34 mutant pediatric GBM sample RMH2465. Bottom, barplot of 
DLX6 expression in a pediatric GBM tissue microarray stratifi ed by  H3F3A status. Blue bars, G34; green, K27; gray, wild-type. ++, strong expression; 
+, moderate expression; −, negative.  SOX2: E, ChIP-Seq of H3K36me3 and RNA polymerase II binding for G34-mutant KNS42 (blue) and wild-type SF188 
cells (gray) for the  SOX2 locus, which also encompasses the  SOX2-OT transcript. F, validation of ChIP-Seq data by ChIP-qPCR using specifi c primers tar-
geting  SOX2 . Blue bars, KNS42; gray, SF188. ***,  P < 0.0001,  t test. G, boxplot of  SOX2 expression in the integrated pediatric GBM samples stratifi ed by 
 H3F3A status. Blue box, G34; green, K27; gray, wild-type. *,  P < 0.05, ANOVA. H, top, immunohistochemistry for SOX2 protein in a G34-mutant pediatric 
GBM sample RMH2465. Bottom, barplot of SOX2 expression in a pediatric GBM tissue microarray stratifi ed by  H3F3A status. Blue bars, G34; green, 
K27; gray, wild-type. ++, strong expression; +, moderate expression; −, negative. 
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 Figure 4.   G34 H3K36me3 upregulates MYCN which is selectively targetable by kinases that destabilize the protein. MYCN: A, ChIP-Seq of 
H3K36me3 and RNA polymerase II binding for G34-mutant KNS42 (blue) and wild-type (wt) SF188 cells (gray) for the  MYCN locus, which also encom-
passes the  MYCNOS transcript. B, validation of ChIP-Seq data by ChIP-qPCR using specifi c primers targeting  MYCN . Blue bars, KNS42; gray, SF188. ***, 
P < 0.0001,  t test. C, boxplot of  MYCN expression in the integrated pediatric GBM samples stratifi ed by  H3F3A status. Blue box, G34; green, K27; 
gray, wild-type. **,  P < 0.01, ANOVA. Wild-type tumors with high mRNA expression were frequently amplifi ed (Amp). D, top, immunohistochemistry for 
MYCN protein in a G34-mutant pediatric GBM sample. RMH2465 bottom, barplot of MYCN expression in a pediatric GBM tissue microarray stratifi ed 
by  H3F3A status. Blue bars, G34; green, K27; gray, wild-type. ++, strong expression; +, moderate expression; −, negative. E, effects on cell viability of 
MYCN knockdown in KNS42 cells. Western blot analysis showing effi ciency of reduction of MYCN by 3 individual siRNAs targeting  MYCN (named 6, 12, 
and W) and a pool of all 3 after 48 and 96 hours. Barplot showing effects on KNS42 cell viability after siRNA knockdown at 7 days. ***,  P < 0.001,  
t test versus control. F, siRNA screen for 714 human kinases in KNS42 cells. Western blot analysis showing expression of MYCN protein in G34-mutant 
KNS42 cells in contrast to a panel of wild-type pediatric glioma lines. GAPDH is used as a loading control. Kinase targets are plotted in plate well order 
along the  x -axis, and  Z scores along the  y -axis.  PLK1 is used as a positive control and is plotted in red. Negative controls are colored light gray, and 
kinases with  Z scores greater than −2.0 (no effect on cell viability) are colored gray. “Hits” ( Z score < −2.0) are colored dark gray or blue, the latter if the 
effect on cell viability is specifi c to KNS42 cells and not in a panel of 4  H3F3A wild-type pediatric glioma cell lines. The most signifi cant and selec-
tive hits were for  CHK1 and  AURKA . G, effect of knockdown of AURKA on MYCN levels in KNS42 cells. Western blot analysis for AURKA and MYCN 
in KNS42 cells treated with individual oligonucleotides directed against AURKA for 48 and 96 hours. GAPDH is used as a loading control. H, effect of 
a selective small-molecule inhibitor of AURKA on MYCN protein levels and cell viability. Left, Western blot analysis for MYCN protein in KNS42 cells 
after exposure to 0.1, 0.5, and 2 to 5 µmol/L VX-689 (triangle). GAPDH is used as a loading control. Right, barplot showing effects on cell viability of 
KNS42 cells exposed to 0.1, 0.5, and 2 to 5 µmol/L VX-689. **,  P < 0.01,  t test versus control. 
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that have been previously associated with stabilization of 
MYCN protein, specifi cally  CHK1 (checkpoint kinase 1; ref. 
 17 ) and  AURKA (aurora kinase A; ref.  18 ). Knockdown of 
 AURKA by an independent set of 4 individual oligonucle-
otides targeting the gene led to a concurrent reduction of 
MYCN protein in KNS42 cells ( Fig. 4G ). This destabilization 
of MYCN was also observed in a dose-dependent manner 
using a highly selective small-molecule inhibitor of  AURKA , 
VX-689 (also known as MK-5108; ref.  19 ), at concentrations, 
which in addition led to a signifi cant reduction in viability of 
the G34-mutant cells ( Fig. 4H ). Together, these data show the 
use of targeting MYCN stability in  H3F3A G34-mutant pedi-
atric GBM as a means of treating this subgroup of patients. 
 DISCUSSION 
 Emerging evidence strongly suggests that pediatric GBMs 
with  H3F3A mutations can be subclassifi ed into distinct 
entities. Our data indicate key molecular and clinical differ-
ences between G34- and K27-mutant tumors, refl ecting the 
anatomic specifi city (K27 tumors restricted to the pons and 
thalamus and G34 to the cerebral hemispheres; ref.  15 ; Sup-
plementary Table S4) and likely distinct developmental origins 
of these disease subgroups. Using the only known model of 
 H3F3A -mutant cells to date, we propose that the gene expres-
sion signature associated with G34 mutation in pediatric GBM 
patient samples is likely driven by a genomic differential bind-
ing of the transcriptionally activating H3K36me3 mark. 
 Mapping these gene expression signatures to publicly avail-
able datasets of human brain development shows a strong 
overlap with the ganglionic eminences of the embryonic and 
early fetal periods. These structures represent a transiently 
proliferating cell mass of the fetal subventricular zone, are the 
source of distinct neuroglial progenitors ( 20 ), and are there-
fore strong candidates for the location of the cells of origin of 
cerebral hemispheric G34-driven pediatric GBM. As with other 
pediatric brain tumors ( 21, 22 ), mutation-driven subgroups of 
GBM retain gene expression signatures related to discrete cell 
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populations from which these distinct tumors may arise. In 
addition, this mutation-driven differential H3K36me3 bind-
ing leads to a signifi cant upregulation of numerous genes 
associated with cell fate decisions. Thus, we have identifi ed a 
transcriptional readout of the likely developmental origin of 
G34-mutant GBM coupled with a self-renewal signature we 
previously identifi ed in KNS42 cells ( 23 ) driven by mutation-
induced differential binding of H3K36me3. 
 Signifi cantly, the G34 mutation additionally upregulates 
MYCN through H3K36me3 binding. It was recently reported 
that the forced overexpression of stabilized MYCN protein in 
neural stem cells of the developing mouse forebrain gave rise 
to GBMs ( 24 ), and thus we provide the mechanism by which 
the initiating tumorigenic insult is delivered at the correct 
time and place ( 25 ) during neurogenesis. Targeting stabiliza-
tion of MYCN protein via synthetic lethality approaches in 
 H3F3A G34-mutant pediatric GBM provides a potential novel 
means of treating this subgroup of patients. 
 METHODS 
 Primary Pediatric Glioblastoma Expression Profi ling 
 Expression data from the Schwartzentruber and colleagues (ref. 
 2 ; GSE34824) and Paugh and colleagues ( 3 GSE19578) studies were 
retrieved from the Gene Expression Omnibus ( www.ncbi.nlm.nih.
gov/geo/ ) and analyzed in GenePattern using a signal-to-noise met-
ric, and GSEA implemented for testing of enrichment of gene lists. 
Pediatric GBM expression signatures were mapped to specifi c devel-
opmental stages and anatomic locations using a spatiotemporal 
gene expression dataset of human brain development in Kang and 
colleagues (ref.  6 ; GSE25219). 
 Tissue Microarrays 
 Immunohistochemistry for  DLX6 (NBP1-85929, Novus Biologi-
cals), SOX2 (EPR3131, Epitomics), and MYCN (#9405, Cell Signal-
ling) was carried out on tissue microarrays consisting of 46 cases of 
pediatric and young adult GBM ascertained for  H3F3A mutation by 
Sanger sequencing. 
 Cell Line Analysis 
 Pediatric GBM KNS42 cells were obtained from the JCRB (Japan 
Cancer Research Resources) cell bank. Pediatric SF188 cells were 
kindly provided by Dr. Daphne Haas-Kogan (University of California 
San Francisco, San Francisco, CA), whereas UW479, Res259, and 
Res186 were kindly provided by Dr. Michael Bobola (University of 
Washington, Seattle, WA). All cells have been extensively characterized 
previously ( 4 ), and were authenticated by short tandem repeat (STR) 
profi ling. Western blot analysis was carried out for total histone H3 
(ab97968, Abcam), as well as H3K36 trimethylation (ab9050, Abcam), 
dimethylation (ab9049, Abcam), and monomethylation (ab9050, 
Abcam), after histone extraction using a histone purifi cation minikit 
(ActiveMotif), and quantitated by scanning on the Storm 860 Molecu-
lar Imager (GE Healthcare) and analyzed using ImageQuant software 
(GE Healthcare). Additional Western blots for MYCN (#9405, Cell 
Signaling), ATRX (sc-15408, Santa Cruz), and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH; #2118, Cell Signaling) were carried 
out according to standard procedures. 
 Chromatin Immunoprecipitation 
 Chromatin immunoprecipitation (ChIP) was carried out using 
antibodies against H3K36me3 and RNA polymerase II using the 
HistonePath and TranscriptionPath assays by ActiveMotif. Whole 
genome sequencing was carried out using an Illumina HiSeq2000 
instrument with a fold coverage of more than 30 fold. Validation 
of active regions was carried out by ChIP-quantitative PCR (qPCR). 
 siRNA Screening and Validation 
 siRNA screening was carried out on a library of 714 human kinases 
using Dharmacon SMARTpools (Dharmacon), with cell viability 
estimated via a highly sensitive luminescent assay measuring cellular 
ATP levels (CellTiter-Glo; Promega).  Z -scores were calculated using 
the median absolute deviation of all effects in each cell line. Individ-
ual ON-TARGETplus oligonucleotides for validation were obtained 
from Dharmacon and knockdown validated by Western blot analysis 
for  AURKA (#4718, Cell Signaling) according to standard procedures 
for up to 96 hours. The  AURKA -selective small-molecule inhibitor 
VX-689 (MK-5108) was obtained from Selleckchem and assayed for 
up to 5 days. Effects on cell viability were assessed by CellTiter-Glo 
(Promega). siRNAs targeting human MYCN were custom designs 
and kindly provided by Janet Shipley (Institute of Cancer Research, 
London, United Kingdom). 
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